Biohaven Ltd. (BHVN) Stock Price & Analysis
Biohaven Ltd. (BHVN) rose 1.90% to USD 15 as of September 10, 2026 at 01:53 UTC, according to Nexqual real-time market data.
BHVN last closed at USD 14.72; the session ranged USD 14.42–15.46 on volume of 2,817,147 shares. Market capitalization is $2.27B, with a 52-week range of USD 7.48–18.57 (NYQ). Source: Nexqual, September 10, 2026 at 01:53 UTC.
Key Statistics (as of September 10, 2026 at 01:53 UTC)
| Price | USD 15 |
|---|---|
| Change | ▲ 1.90% (up) |
| Previous Close | USD 14.72 |
| Open | USD 14.62 |
| Day Range | USD 14.42 – 15.46 |
| 52-Week Range | USD 7.48 – 18.57 |
| Volume | 2,817,147 shares |
| Market Cap | $2.27B |
| Exchange | NYQ |
Technical Analysis (BHVN)
Nexqual's technical model rates BHVN "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of September 10, 2026 at 01:53 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 50.11 (neutral) |
| vs SMA50 | Above (USD 14.83) |
| MACD | 0.29 (positive) |
Analyst Ratings (BHVN)
Wall Street analysts rate BHVN "Buy" based on 15 analysts, with a mean price target of USD 21.47 (range USD 10–42), per Nexqual as of September 10, 2026 at 01:53 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 21.47 |
| High Target | USD 42 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 12 / 3 / 1 |
Earnings (BHVN)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -0.21 |
| Revenue Estimate | $25.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.78 vs est -0.61 ▼ miss |
| 2026-03-31 | USD -0.69 vs est -0.76 ▲ beat |
| 2025-12-31 | USD -0.9 vs est -0.96 ▲ beat |
| 2025-09-30 | USD -1.47 vs est -1.54 ▲ beat |
Source: Nexqual, September 10, 2026 at 01:53 UTC.
Financials & Fundamentals (BHVN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -799.46% |
| Debt / Equity | 2,430.33 |
| Current Ratio | 4.73 |
| Total Cash | $267.87M |
| Total Debt | $297.04M |
| Free Cash Flow | $-256.22M |
Source: Nexqual, September 10, 2026 at 01:53 UTC.
Financial Health Score (BHVN)
Nexqual rates Biohaven Ltd.'s overall financial health "Weak" across five dimensions, as of September 10, 2026 at 01:53 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $268M cash vs $297M debt |
| Cash Flow | Weak — Operating cash flow -$511M |
| Efficiency | Critical — ROE -799%, ROA -72.0% |
Ownership (BHVN)
| Insider Ownership | +11.21% |
|---|---|
| Institutional Ownership | +96.66% |
| Shares Outstanding | 151.04M |
| Float | 116.57M |
| Short % of Float | +15.09% |
Source: Nexqual, September 10, 2026 at 01:53 UTC.
Leadership (BHVN)
Biohaven Ltd. is led by Vladimir Coric (age 54), Chairman & CEO, per Nexqual as of September 10, 2026 at 01:53 UTC.
| Chairman & CEO | Vladimir Coric (age 54) |
|---|---|
| Chief Financial Officer | Matthew Buten (age 64) |
| Senior Vice President of Clinical Operations | Kimberly Gentile (age 59) |
| Senior Director of Regulatory Affairs & Operations | Deb Young |
| Chief Technology Officer | John McGill |
Major Backers & Investors (BHVN)
Notable institutional backers of Biohaven Ltd. include Montanova Capital LLC, Stifel Financial Corporation, Jupiter Topco LLC, according to Nexqual as of September 10, 2026 at 01:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Montanova Capital LLC | 6.81% |
| Stifel Financial Corporation | 6.58% |
| Jupiter Topco LLC | 5.68% |
| Woodline Partners LP | 5.07% |
| Infinitum Asset Management, LLC | 4.14% |
| Shaw D.E. & Co., Inc. | 2.77% |
| AQR Capital Management, LLC | 2.75% |
| Fidelity | 2.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.87% |
| State Street | 7.07% |
Source: Nexqual, September 10, 2026 at 01:53 UTC.
From Biohaven Ltd.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.
- The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors.
- In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DNLI | Denali Therapeutics Inc. | USD 21.57 | ▼ 3.19% |
| BBIO | BridgeBio Pharma, Inc. | USD 76.08 | ▲ 1.66% |
| ARVN | Arvinas, Inc. | USD 8.76 | ▼ 6.71% |
| RARE | Ultragenyx Pharmaceutical Inc. | USD 14.31 | ▼ 6.47% |
| MDGL | Madrigal Pharmaceuticals, Inc. | USD 546.66 | ▲ 1.03% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 10, 2026 at 01:53 UTC. This page is informational and not investment advice.